Cellebrite DI (CLBT) stock rose 4.4% following the company's announcement of record fourth-quarter and full-year 2025 results on February 11, 2026. The company reported total annual recurring revenue grew 21% to $480.8 million, with quarterly revenue of $128.8 million, up 18% year-over-year. Net income reached $21.3 million with adjusted EBITDA of $38.3 million and a 29.8% adjusted EBITDA margin. The company provided a 2026 outlook projecting ARR reaching up to $573 million. Despite some analyst price target reductions following the earnings announcement, the consensus rating remained Moderate Buy with an average price target of $22.50. The stock had previously reached a new 52-week low of $12.34 on February 23, 2026.
Read full analysisCellebrite DI (CLBT) stock rose 4.4% following the company's announcement of record fourth-quarter and full-year 2025 results on February 11, 2026. The company reported total annual recurring revenue grew 21% to $480.8 million, with quarterly revenue of $128.8 million, up 18% year-over-year. Net income reached $21.3 million with adjusted EBITDA of $38.3 million and a 29.8% adjusted EBITDA margin. The company provided a 2026 outlook projecting ARR reaching up to $573 million. Despite some analyst price target reductions following the earnings announcement, the consensus rating remained Moderate Buy with an average price target of $22.50. The stock had previously reached a new 52-week low of $12.34 on February 23, 2026.
Cellebrite is an Israeli-founded digital intelligence company that provides AI-powered forensic tools used by law enforcement, defense, and intelligence agencies to extract and analyze data from mobile devices and digital sources. The company reported record Q4 2025 results with 21% ARR growth to $480.8 million, but soft Q1 guidance, a TD Cowen downgrade citing market contraction, and price target cuts from Deutsche Bank and Needham triggered a seven-session rout that erased roughly 35% of the stock's value. Today's bounce comes after shares hit a 52-week low, with the analyst consensus price target of $22.50 now sitting roughly 80% above the current price.